Lipid Nanoparticles for Ocular Gene Delivery
Open accessThe DOI matches its Crossref record; 97 of the 99 references it cites were found in a registry or an index.
Abstract
Lipids contain hydrocarbons and are the building blocks of cells. Lipids can naturally form themselves into nano-films and nano-structures, micelles, reverse micelles, and liposomes. Micelles or reverse micelles are monolayer structures, whereas liposomes are bilayer structures. Liposomes have been recognized as carriers for drug delivery. Solid lipid nanoparticles and lipoplex (liposome-polycation-DNA complex), also called lipid nanoparticles, are currently used to deliver drugs and genes to ocular tissues. A solid lipid nanoparticle (SLN) is typically spherical, and possesses a solid lipid core matrix that can solubilize lipophilic molecules. The lipid nanoparticle, called the liposome protamine/DNA lipoplex (LPD), is electrostatically assembled from cationic liposomes and an anionic protamine-DNA complex. The LPD nanoparticles contain a highly condensed DNA core surrounded by lipid bilayers. SLNs are extensively used to deliver drugs to the cornea. LPD nanoparticles are used to target the retina. Age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy are the most common retinal diseases in humans. There have also been promising results achieved recently with LPD nanoparticles to deliver functional genes and micro RNA to treat retinal diseases. Here, we review recent advances in ocular drug and gene delivery employing lipid nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Liposomes-protamine-DNA (LPD), in combination with a nuclear localization signal (NLS) peptide and a transactivator of transcription (TAT) peptide, make cell-specific and efficient gene delivery with sustained gene expression [35].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978 · cited 1×
“In the final analysis, liposomes depend on continually improving the formulation of the nanoparticles’ coating and DNA design to increase the transfection efficiency [76,77].”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 1×
“Liposomes were first identified in 1965 [63], and were successfully applied as cationic liposome complexes via intravenous DNA delivery into adult mice in 1993.”
Jain, P. K., Huang, X., El-Sayed, I. H., & El-Sayed, M. A. (2008) · Accounts of Chemical Research · doi:10.1021/ar7002804 · Cited by 4,215 · cited 1×
“Therefore, liposomes are artificial phospholipid bilayers; as a result, liposomes have biocompatible characteristics [49,50].”
BackgroundIn Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416 · cited 1×
“The TAT-fusions have been shown to cross the blood–brain barrier [81].”
BackgroundSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In clinical trials, three independent groups reported vision improvements upon the viral-mediated delivery of the Rpe65 gene in patients with Rpe65-associated Leber’s congenital amaurosis (LCA) [89–91].”
BackgroundNew-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“In clinical trials, three independent groups reported vision improvements upon the viral-mediated delivery of the Rpe65 gene in patients with Rpe65-associated Leber’s congenital amaurosis (LCA) [89–91].”
BackgroundThe Basic Science of Gene Therapy
Mulligan, R. C. (1993) · Science · doi:10.1126/science.8493530 · Cited by 1,741 · cited 1×
“The success of gene therapy relies on the development of efficient, non-toxic gene carriers that can encapsulate and deliver foreign genetic materials into specific cell types [26].”
BackgroundFutaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., & Sugiura, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007540200 · Cited by 1,662
Green, M., & Loewenstein, P. M. (1988) · Cell · doi:10.1016/0092-8674(88)90262-0 · Cited by 1,553 · cited 1×
“In 1988, the first CPP was sequenced from an HIV-1-encoded cell-penetrating transactivator of transcription (TAT) peptide, and delivered efficiently through cell membranes; TAT has been widely applied since then [83–85].”
MethodGaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
TORCHILIN, V (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.009 · Cited by 1,273
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Mechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection,
Xu, Y., & Szoka, F. C. (1996) · Biochemistry · doi:10.1021/bi9602019 · Cited by 1,134 · cited 3×
“Such enclosure also increases the likelihood of endocytosis and uptake of nucleic acids or drugs into cells [4,20,55].”
BackgroundEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 1×
“restricts the insertion of genes to <5 kb, is another limitation [30].”
BackgroundRpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929 · cited 1×
“Without the photochemical, we lose the ability to see light [88].”
BackgroundNanotechnology with Soft Materials
Hamley, I. W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200546 · Cited by 914 · cited 1×
“Lipids can naturally form themselves into nano-films and nano-structures, called micelles, reverse micelles, and liposomes [20,48].”
BackgroundTorchilin, V. P., Rammohan, R., Weissig, V., & Levchenko, T. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151247498 · Cited by 777 · cited 1×
“In the final analysis, liposomes depend on continually improving the formulation of the nanoparticles’ coating and DNA design to increase the transfection efficiency [76,77].”
BackgroundSystemic Gene Expression After Intravenous DNA Delivery into Adult Mice
Zhu, N., Liggitt, D., Liu, Y., & Debs, R. (1993) · Science · doi:10.1126/science.7687073 · Cited by 720 · cited 1×
“Since then, liposomes have been successful and widely applied in nanotechnology [64] and in various medical fields [23,24,61,65,66].”
BackgroundAn overview of current delivery systems in cancer gene therapy
El-Aneed, A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.09.013 · Cited by 693 · cited 3×
“polymers like polyethylenimine (PEI) [56] and poly L-lysine (PLL) [57], peptides, liposomes (tiny fat-like particles) [58], and liposomes-protamine-DNA (LPD) complexes [59,60].”
BackgroundCideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., Pang, J.-J., Sumaroka, A., Windsor, E. A. M., Wilson, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807027105 · Cited by 673 · cited 1×
“In clinical trials, three independent groups reported vision improvements upon the viral-mediated delivery of the Rpe65 gene in patients with Rpe65-associated Leber’s congenital amaurosis (LCA) [89–91].”
BackgroundHerz, J., & Gerard, R. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.7.2812 · Cited by 517 · cited 1×
“adeno-associated virus (AAV), have attractive features, particularly their high gene transduction capability, they face biosafety issues, especially innate and immune barriers [27], toxicity [28], and potential recombination of or complementation [29] to vector delivery.”
BackgroundIn vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes
Li, S., & Huang, L. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300482 · Cited by 475 · cited 3×
“Another advantage of protamine is that the encapsulated DNA is protected from nuclease degradation [23,59].”
BackgroundSchwarze, S. R., & Dowdy, S. F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01429-7 · Cited by 452 · cited 1×
“In designing our recently formulated lipid nanoparticle, we used a nuclear localization peptide derived from SV40 T antigen (DKKKRKVDKKKRKVDKKKRKV), and another peptide derived from human immunodeficiency virus transactivator of transcription (TAT; YGRKKRRQRRR) peptide [79–82].”
MethodPhospholipid spherules (liposomes) as a model for biological membranes
Sessa, G., & Weissmann, G. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43097-4 · Cited by 446
Possible Existence of Common Internalization Mechanisms among Arginine-rich Peptides
Suzuki, T., Futaki, S., Niwa, M., Tanaka, S., Ueda, K., & Sugiura, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110017200 · Cited by 430 · cited 1×
“However, the mechanism is not explained by either adsorptive-mediated endocytosis or by receptor-mediated endocytosis [62,86,87].”
BackgroundSolid lipid nanoparticles (SLN) as ocular delivery system for tobramycin
Cavalli, R., Gasco, M. R., Chetoni, P., Burgalassi, S., & Saettone, M. F. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00080-7 · Cited by 389 · cited 3×
“The majority of solid lipid nanoparticles have been used to deliver drugs to the cornea [9,13,16,17,21,22].”
BackgroundTAT-Mediated Protein Transduction into Mammalian Cells
Becker-Hapak, M., McAllister, S. S., & Dowdy, S. F. (2001) · Methods · doi:10.1006/meth.2001.1186 · Cited by 384 · cited 1×
“In designing our recently formulated lipid nanoparticle, we used a nuclear localization peptide derived from SV40 T antigen (DKKKRKVDKKKRKVDKKKRKV), and another peptide derived from human immunodeficiency virus transactivator of transcription (TAT; YGRKKRRQRRR) peptide [79–82].”
MethodCharacterization of cationic lipid-protamine–DNA (LPD) complexes for intravenous gene delivery
Li, S., Rizzo, M., Bhattacharya, S., & Huang, L. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300683 · Cited by 369 · cited 1×
“polymers like polyethylenimine (PEI) [56] and poly L-lysine (PLL) [57], peptides, liposomes (tiny fat-like particles) [58], and liposomes-protamine-DNA (LPD) complexes [59,60].”
TAT transduction: the molecular mechanism and therapeutic prospects
Gump, J. M., & Dowdy, S. F. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.002 · Cited by 356 · cited 1×
“In designing our recently formulated lipid nanoparticle, we used a nuclear localization peptide derived from SV40 T antigen (DKKKRKVDKKKRKVDKKKRKV), and another peptide derived from human immunodeficiency virus transactivator of transcription (TAT; YGRKKRRQRRR) peptide [79–82].”
MethodAdenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Toxicity Study
Simon, R. H., Engelhardt, J. F., Yang, Y., Zepeda, M., Weber-Pendleton, S., Grossman, M., & Wilson, J. M. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.6-771 · Cited by 323 · cited 1×
“adeno-associated virus (AAV), have attractive features, particularly their high gene transduction capability, they face biosafety issues, especially innate and immune barriers [27], toxicity [28], and potential recombination of or complementation [29] to vector delivery.”
BackgroundFarkhani, S. M., Valizadeh, A., Karami, H., Mohammadi, S., Sohrabi, N., & Badrzadeh, F. (2014) · Peptides · doi:10.1016/j.peptides.2014.04.015 · Cited by 273 · cited 1×
“In 1988, the first CPP was sequenced from an HIV-1-encoded cell-penetrating transactivator of transcription (TAT) peptide, and delivered efficiently through cell membranes; TAT has been widely applied since then [83–85].”
MethodBeltran, W. A., Cideciyan, A. V., Lewin, A. S., Iwabe, S., Khanna, H., Sumaroka, A., Chiodo, V. A., Fajardo, D. S., Román, A. J., Deng, W.-T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118847109 · Cited by 260 · cited 2×
“Virus AAV Local/systemic [31–35] Adenovirus Local [36] Baculovirus Local [37,38] Lentivirus Local [39]”
BackgroundGreen, M., Ishino, M., & Loewenstein, P. M. (1989) · Cell · doi:10.1016/0092-8674(89)90417-0 · Cited by 256 · cited 1×
“In 1988, the first CPP was sequenced from an HIV-1-encoded cell-penetrating transactivator of transcription (TAT) peptide, and delivered efficiently through cell membranes; TAT has been widely applied since then [83–85].”
MethodSolid lipid nanoparticles for ocular drug delivery
Seyfoddin, A., Shaw, J., & Al-Kassas, R. (2010) · Drug Delivery · doi:10.3109/10717544.2010.483257 · Cited by 247 · cited 4×
“The majority of solid lipid nanoparticles have been used to deliver drugs to the cornea [9,13,16,17,21,22].”
BackgroundInfluentialDrug transport to brain with targeted liposomes
Schnyder, A., & Huwyler, J. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.99 · Cited by 210 · cited 2×
“Remarkably, liposomes can entrap and protect drug molecules or nucleic acids on the journey to the target site [54].”
BackgroundMashaghi, S., Jadidi, T., Koenderink, G., & Mashaghi, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14024242 · Cited by 210 · cited 3×
“Such enclosure also increases the likelihood of endocytosis and uptake of nucleic acids or drugs into cells [4,20,55].”
BackgroundThe use of DNA viruses as vectors for gene therapy.
Ali, M., Lemoine, N. R., & Ring, C. (1994) · PubMed · Cited by 200
Attama, A. A., Reichl, S., & Müller-Goymann, C. C. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.12.007 · Cited by 200 · cited 3×
“The majority of solid lipid nanoparticles have been used to deliver drugs to the cornea [9,13,16,17,21,22].”
BackgroundByrne, L. C., Dalkara, D., Luna, G., Fisher, S. K., Clérin, E., Sahel, J.-A., Léveillard, T., & Flannery, J. G. (2015) · Journal of Clinical Investigation · doi:10.1172/jci65654 · Cited by 182 · cited 1×
“Virus AAV Local/systemic [31–35] Adenovirus Local [36] Baculovirus Local [37,38] Lentivirus Local [39]”
BackgroundSeyfoddin, A., & Al-Kassas, R. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.665460 · Cited by 164 · cited 4×
“The majority of solid lipid nanoparticles have been used to deliver drugs to the cornea [9,13,16,17,21,22].”
BackgroundInfluentialFeasibility of Lipid Nanoparticles for Ocular Delivery of Anti-Inflammatory Drugs
Souto, E. B., Doktorovová, S., González‐Mira, E., Egea, M. A., & García, M. L. (2010) · Current Eye Research · doi:10.3109/02713681003760168 · Cited by 164 · cited 1×
“Lipid nanoparticles have also been shown to be feasible for the ocular delivery of anti-inflammatory drugs [12].”
BackgroundCyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity
Gokce, E. H., Sandri, G., Bonferoni, M. C., Rossi, S., Ferrari, F., Güneri, T., & Caramella, C. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.028 · Cited by 159 · cited 1×
“Cyclosporine is commonly prescribed for chronic dry eye, caused by inflammation, and cyclosporine A-loaded solid lipid nanoparticles have been shown to improve drug efficacy when administered to rabbit eyes [14,15].”
BackgroundLiposomes and nanotechnology in drug development: focus on ocular targets
Honda, M., Asai, Oku, Araki, Tanaka, & Ebihara (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s30725 · Cited by 157
Biodistribution and transgene expression with nonviral cationic vector/DNA complexes in the lungs
Bragonzi, A., Dina, G., Villa, A., Calori, G., Biffi, A., Bordignon, C., Assael, B. M., & Conese, M. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301282 · Cited by 151 · cited 2×
“polymers like polyethylenimine (PEI) [56] and poly L-lysine (PLL) [57], peptides, liposomes (tiny fat-like particles) [58], and liposomes-protamine-DNA (LPD) complexes [59,60].”
DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64833 · Cited by 150 · cited 2×
“Compacted DNA nanoparticles formulated with polyethylene glycol-substituted polylysine have been used for gene therapy in mouse models of eye diseases [5–8].”
BackgroundMethodThe University of North Carolina at Chapel Hill University Libraries (2015) · The University of North Carolina at Chapel Hill University Libraries · doi:10.17615/2x9m-k248 · Cited by 145
Lipoplex Formation under Equilibrium Conditions Reveals a Three-Step Mechanism
Oberle, V., Bakowsky, U., Zuhorn, I. S., & Hoekstra, D. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76396-x · Cited by 135 · cited 1×
“Such enclosure also increases the likelihood of endocytosis and uptake of nucleic acids or drugs into cells [4,20,55].”
BackgroundDrug and Gene Delivery to the Back of the Eye: From Bench to Bedside
Rowe-Rendleman, C. L., Durazo, S. A., Kompella, U. B., Rittenhouse, K. D., Di Polo, A., Weiner, A. L., Grossniklaus, H. E., Naash, M. I., Lewin, A. S., Horsager, A., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13707 · Cited by 120 · cited 2×
“Compacted DNA nanoparticles formulated with polyethylene glycol-substituted polylysine have been used for gene therapy in mouse models of eye diseases [5–8].”
BackgroundMethodRajala, A., Wang, Y., Zhu, Y., Ranjo-Bishop, M., Ma, J.-X., Mao, C., & Rajala, R. V. S. (2014) · Nano Letters · doi:10.1021/nl502275s · Cited by 117 · cited 11×
“Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8]”
BackgroundInfluentialSelf-citationBemelmans, A.-P., Kostic, C., Crippa, S. V., Hauswirth, W. W., Lem, J., Munier, F. L., Seeliger, M. W., Wenzel, A., & Arsenijevic, Y. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030347 · Cited by 117 · cited 3×
“method of restoring vision is comparable to AAV [93] and lentiviral [39] gene transfer of the Rpe65 gene to Rpe65 knockout mice.”
BackgroundMethodNanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107 · cited 1×
“The cytomegalovirus (CMV) promoter is widely used, due to its ability to induce protein expression in varied cell types [1,23].”
BackgroundDelgado, D., del Pozo‐Rodríguez, A., Solinís, M. Á., & Rodríguez‐Gascón, A. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.06.005 · Cited by 104 · cited 2×
“the presence of a nuclear localization signal [68].”
BackgroundTAT conjugated cationic noble metal nanoparticles for gene delivery to epidermal stem cells
Peng, L., Niu, J., Zhang, C., Yu, W., Wu, J., Shan, Y.-H., Wang, X.-R., Shen, Y., Mao, Z., Liang, W., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.062 · Cited by 103 · cited 1×
“However, the mechanism is not explained by either adsorptive-mediated endocytosis or by receptor-mediated endocytosis [62,86,87].”
BackgroundNanoparticles for retinal gene therapy
Conley, S. M., & Naash, M. I. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.004 · Cited by 101 · cited 1×
“displaces the DNA from the complex and allows DNA to enter into the cytoplasm [4,74,75].”
BackgroundNanomicelles: an Emerging Platform for Drug Delivery to the Eye
Vadlapudi, A. D., & Mitra, A. K. (2013) · Therapeutic Delivery · doi:10.4155/tde.12.122 · Cited by 101 · cited 1×
“Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8]”
Backgrounddel Pozo‐Rodríguez, A., Delgado, D., Solinís, M. Á., Rodríguez‐Gascón, A., & Pedraz, J. L. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.023 · Cited by 100 · cited 1×
“Solid lipid nanoparticles have also been used for retinal gene therapy and to study intracellular trafficking in RPE cells [18].”
BackgroundLai, C., Yu, M. J. T., Brankov, M., Barnett, N. L., Zhou, X., Redmond, T. M., Narfström, K. L., & Rakoczy, P. E. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-3 · Cited by 100
Lipid Nanoparticles as Drug/Gene Delivery Systems to the Retina
del Pozo-Rodríguez, A., Delgado, D., Gascón, A. R., & Solinís, M. Á. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0128 · Cited by 98 · cited 3×
“Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8]”
BackgroundLiu, H.-A., Liu, Y.-L., Ma, Z.-Z., Wang, J.-C., & Zhang, Q. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5891 · Cited by 97 · cited 1×
“Lipid nanoparticles have also been used to improve the efficiency of siRNA delivery in RPE cells and a laser-induced rat model for the treatment of choroidal neovascularization [10].”
Backgroundvan Rooijen, N., & van Nieuwmegen, R. (1980) · Immunological Communications · doi:10.3109/08820138009065997 · Cited by 96
Gokce, E. H., Sandri, G., Eğrilmez, S., Bonferoni, M. C., Güneri, T., & Caramella, C. M. (2009) · Current Eye Research · doi:10.3109/02713680903261405 · Cited by 84
Comparative Analysis of DNA Nanoparticles and AAVs for Ocular Gene Delivery
Han, Z., Conley, S. M., Makkia, R., Guo, J., Cooper, M. J., & Naash, M. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052189 · Cited by 82
A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide
Li, R., Jiang, S., Liu, D., Bi, X., Wang, F., Zhang, Q., & Xu, Q. (2010) · Journal of Microencapsulation · doi:10.3109/02652048.2010.539304 · Cited by 81 · cited 2×
“Methazolamide (MTA) is an anti-glaucoma drug; however, systemic administration produces side effects, while providing insufficient ocular therapeutic concentrations [11].”
BackgroundRPE65 Gene Delivery Restores Isomerohydrolase Activity and Prevents Early Cone Loss in Rpe65−/−Mice
Chen, Y., Moiseyev, G., Takahashi, Y., & Ma, J.-X. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0965 · Cited by 80
Attama, A. A., Reichl, S., & Müller-Goymann, C. C. (2009) · Current Eye Research · doi:10.1080/02713680903017500 · Cited by 80 · cited 4×
“The majority of solid lipid nanoparticles have been used to deliver drugs to the cornea [9,13,16,17,21,22].”
BackgroundInfluentialGandra, N., Wang, D., Zhu, Y., & Mao, C. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201301113 · Cited by 80 · cited 2×
“One approach for more successful nanoparticle gene therapy is the liposome protamine/DNA lipoplex (LPD), which is applied as a two-step packaging technology employing a multilayering method [61,67].”
BackgroundMethodMa, K., Wang, D., Lin, Y., Wang, J., Petrenko, V., & Mao, C. (2013) · Advanced Functional Materials · doi:10.1002/adfm.201102963 · Cited by 77 · cited 8×
“Since then, liposomes have been successful and widely applied in nanotechnology [64] and in various medical fields [23,24,61,65,66].”
BackgroundMethodInfluentialPozzi, D., Marchini, C., Cardarelli, F., Salomone, F., Coppola, S., Montani, M., Elexpuru-Zabaleta, M., Digman, M. A., Gratton, E., Colapicchioni, V., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.11.014 · Cited by 76 · cited 2×
“displaces the DNA from the complex and allows DNA to enter into the cytoplasm [4,74,75].”
BackgroundKoirala, A., Makkia, R. S., Conley, S. M., Cooper, M. J., & Naash, M. I. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt013 · Cited by 75 · cited 3×
“Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8]”
BackgroundMethodAdvances in AAV Vector Development for Gene Therapy in the Retina
Day, T. P., Byrne, L. C., Schaffer, D. V., & Flannery, J. G. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_86 · Cited by 71 · cited 1×
“the advantage in cellular entry, because they bind to the cellular receptors and co-receptors, which help them to internalize and traffic to the nucleus [69–73].”
BackgroundA review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium
Koirala, A., Conley, S. M., & Naash, M. I. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.002 · Cited by 71 · cited 1×
“the advantage in cellular entry, because they bind to the cellular receptors and co-receptors, which help them to internalize and traffic to the nucleus [69–73].”
BackgroundRPE65 gene therapy slows cone loss in Rpe65-deficient dogs
Mowat, F. M., Breuwer, A. R., Bartoe, J. T., Annear, M. J., Zhang, Z., Smith, A. J., Bainbridge, J. W., Petersen‐Jones, S. M., & Ali, R. R. (2012) · Gene Therapy · doi:10.1038/gt.2012.63 · Cited by 70
Wang, F., & Liu, J. (2014) · Small · doi:10.1002/smll.201400850 · Cited by 70 · cited 1×
“into the genetic machinery for gene expression [1–4].”
BackgroundIncorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement
Shen, J., Sun, M., Ping, Q. N., Zhi, Y., & Liu, W. (2009) · Nanotechnology · doi:10.1088/0957-4484/21/2/025101 · Cited by 68 · cited 6×
“Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8]”
BackgroundInfluentialEffects of Sterols on the Therapeutic Efficacy of Liposomal Amphotericin B in Murine Candidiasis
Lopez‐Berestein, G., Mehta, R. T., Hopfer, R. L., Mehta, K., Hersh, E. M., & Juliano, R. L. (1983) · Cancer Drug Delivery · doi:10.1089/cdd.1983.1.37 · Cited by 65 · cited 1×
“This biocompatibility accounts for their most important advantages as drug carriers, (1) liposomes have almost no toxicity and low antigenicity; (2) liposomes can be biodegraded and metabolized in vivo, and (3) liposomal properties, such as membrane permeability, can be controlled to some extent [51–53].”
BackgroundLi, X., Li, W., Dai, X., Kong, F., Zheng, Q., Zhou, X., Lü, F., Chang, B., Rohrer, B., Hauswirth, W. W., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6138 · Cited by 64 · cited 2×
“Virus AAV Local/systemic [31–35] Adenovirus Local [36] Baculovirus Local [37,38] Lentivirus Local [39]”
BackgroundTakahashi, Y., Chen, Q., Rajala, R. V. S., & Ma, J.-X. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.03.010 · Cited by 60
Self-citationNovel Dexamethasone-Loaded Nanomicelles for the Intermediate and Posterior Segment Uveitis
Vaishya, R. D., Gokulgandhi, M. R., Patel, S. P., Minocha, M., & Mitra, A. K. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0100-4 · Cited by 58 · cited 1×
“Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8]”
BackgroundHoare, M., Greiser, U., Schu, S., Mashayekhi, K., Aydogan, E., Murphy, M. J., Barry, F., Ritter, T., & O’Brien, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1426 · Cited by 54 · cited 1×
“Nuclear localization peptide of the SV40 T large antigen has been shown to promote high LPD-mediated transfection efficiency [23,24,61,78].”
BackgroundKoirala, A., Conley, S. M., Makkia, R., Liu, Z., Cooper, M. J., Sparrow, J. R., & Naash, M. I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.299 · Cited by 47 · cited 2×
“Compacted DNA nanoparticles formulated with polyethylene glycol-substituted polylysine have been used for gene therapy in mouse models of eye diseases [5–8].”
BackgroundMethodHan, Z., Conley, S. M., & Naash, M. I. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6916 · Cited by 40 · cited 1×
“Many unique genes have been associated with major retinal diseases, such as retinitis pigmentosa (RP), Leber’s congenital amaurosis (LCA), and Stargardt disease [65,69,95].”
BackgroundVadlapudi, A. D., Vadlapatla, R. K., Earla, R., Sirimulla, S., Bailey, J., Pal, D., & Mitra, A. K. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1059-7 · Cited by 38 · cited 1×
“Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8]”
BackgroundKollen, W. J. W., Mulberg, A. E., Wei, X., Sugita, M., Raghuram, V., Wang, J., Foskett, J. K., Glick, M. C., & Scanlin, T. F. (1999) · Human Gene Therapy · doi:10.1089/10430349950018689 · Cited by 38 · cited 2×
“polymers like polyethylenimine (PEI) [56] and poly L-lysine (PLL) [57], peptides, liposomes (tiny fat-like particles) [58], and liposomes-protamine-DNA (LPD) complexes [59,60].”
Mao, Y., Triantafillou, G., Hertlein, E. K., Towns, W. H., Stefanovski, M. R., Mo, X. M., Jarjoura, D. G., Phelps, M. A., Marcucci, G., Lee, L. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2046 · Cited by 35 · cited 1×
“Since then, liposomes have been successful and widely applied in nanotechnology [64] and in various medical fields [23,24,61,65,66].”
BackgroundClinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis
Stein, L., Roy, K., Lei, L., & Kaushal, S. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.557358 · Cited by 35 · cited 1×
“Further studies are needed to determine how retinal gene therapy can be improved [96,97].”
BackgroundMontasser, I., Shahgaldian, P., Perret, F., & Coleman, A. W. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121899 · Cited by 34 · cited 1×
“Solid lipid nanoparticles and lipid nanoparticles have been extensively reviewed and described in detailed in recently published articles [19,20].”
BackgroundEmerging Gene Therapies for Retinal Degenerations
Cepko, C. L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0295-12.2012 · Cited by 33 · cited 2×
“Virus AAV Local/systemic [31–35] Adenovirus Local [36] Baculovirus Local [37,38] Lentivirus Local [39]”
Kuznetsova, N. R., & Vodovozova, E. L. (2014) · Biochemistry (Moscow) · doi:10.1134/s0006297914080070 · Cited by 31 · cited 1×
“into the genetic machinery for gene expression [1–4].”
BackgroundEducational paper: Retinal dystrophies and gene therapy
Sundaram, V., Moore, A. T., Ali, R. R., & Bainbridge, J. W. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1615-2 · Cited by 30
Cao, B., Qiu, P., & Mao, C. (2013) · Microscopy Research and Technique · doi:10.1002/jemt.22251 · Cited by 25 · cited 1×
“LPD has been used to successfully deliver the vascular endothelial growth factor gene into mesenchymal stem cells [25].”
MethodLuz-Madrigal, A., Clapp, C., Aranda, J., & Vaca, L. A. (2007) · Virology Journal · doi:10.1186/1743-422x-4-88 · Cited by 25 · cited 2×
“Virus AAV Local/systemic [31–35] Adenovirus Local [36] Baculovirus Local [37,38] Lentivirus Local [39] Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8] Despite rapid advances in gene therapy during the last two decade…”
BackgroundHow to avoid complement attack in baculovirus-mediated gene delivery
Kaikkonen, M. U., Ylä‐Herttuala, S., & Airenne, K. J. (2011) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2011.05.007 · Cited by 24 · cited 2×
“Virus AAV Local/systemic [31–35] Adenovirus Local [36] Baculovirus Local [37,38] Lentivirus Local [39] Non-virus Liposome nanoparticles Local [40–43] Solid lipid nanoparticles Local [9,13,16,17,21,22] LPD/lipoplexes Local [23,24,44] CK30-PEG Local [5–8] Despite rapid advances in gene therapy during the last two decade…”
BackgroundLiposomes as vehicles for cellular incorporation of biologically active macromolecules
Paphadiopoulos, D., Wilson, T., & Taber, R. (1980) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/bf02618199 · Cited by 19 · cited 1×
“The liposome can be used as a transport vehicle to send nutrients and drugs into the body [45–47].”
BackgroundGene Therapy for Retinal Dystrophies: Twenty Years in the Making
Ali, R. R. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.2506 · Cited by 12 · cited 1×
“Many unique genes have been associated with major retinal diseases, such as retinitis pigmentosa (RP), Leber’s congenital amaurosis (LCA), and Stargardt disease [65,69,95].”
BackgroundBemelmans, A., Kostic, C., Hornfeld, D., Jaquet, M., Crippa, S. V., Hauswirth, W. W., Lem, J., Wang, Z., Schorderet, D. F., Munier, F. L., et al. (2006) · Advances in experimental medicine and biology · doi:10.1007/0-387-32442-9_35 · Cited by 11
Cornea-targeted gene therapy using adenovirus vector
Park, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.042 · Cited by 2
Research works printed but not linked: 1
- Immordino, 2006, Stealth liposomes, review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomedicine., 1, 297
Cited by
Solid lipid nanoparticles: a review on recent perspectives and patents
Paliwal, R., Paliwal, S. R., Kenwat, R., Kurmi, B. D., & Sahu, M. K. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1720649 · Cited by 337
“20 Ocular gene delivery Lipid Nanoparticles for Ocular Gene Delivery [47] 21 Topical immunization A highlight on lipid based nanocarriers for transcutaneous immunization [48] 22 Nucleic acid delivery Solid lipid nanoparticles as nucleic acid delivery system: properties and molecular mechanisms [49] 23 Topical delivery…”
BackgroundPrasad, M., Lambe, U. P., Brar, B., Shah, I., J, M., Ranjan, K., Rao, R., Kumar, S., Mahant, S., Khurana, S. K., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.026 · Cited by 327
A review on recent drug delivery systems for posterior segment of eye
Nayak, K., & Misra, M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.138 · Cited by 225
Ocular delivery of proteins and peptides: Challenges and novel formulation approaches
Mandal, A., Pal, D., Agrahari, V., Trinh, H. M., Joseph, M., & Mitra, A. K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.008 · Cited by 225
“Both SLNs and NLCs have shown potential in delivering small molecules to ocular tissues [171-173].”
BackgroundNanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez-Gascón, A., Solinís, M. Á., & del Pozo-Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 223
Metadata
- Authors
- Wang, Y., Rajala, A., & Rajala, R.
- Affiliations
- Dean McGee Eye Institute (US)
- Corresponding author
- Rajala, Raju
- Venue
- Journal of Functional Biomaterials
- Publisher
- MDPI AG
- Published
- 2015-06-08
- Volume
- 6
- Issue
- 2
- Pages
- 379-394
- ISSN
- 2079-4983 (ISSN-L)
- PMC
- PMC4493518
- OpenAlex
- W1506466933
- Cited by
- 93
- References
- 99
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 2 · 2023: 9 · 2022: 12 · 2021: 12 · 2020: 6 · 2019: 7 · 2018: 10 · 2017: 7 · 2016: 9 · 2015: 3
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Functional Biomaterials (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- NIH (EY016507, EY00871, EY021725)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, ocular gene delivery, solid lipid nanoparticles, lipoplexes, liposomes, corneal drug delivery, retinal gene therapy, age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, microRNA delivery, retinal disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.